Cyclic-di-GMP

• UNSPSC Description:

  Cyclic-di-GMP is a STING agonist and a bacterial second messenger that coordinates different aspects of bacterial growth and behavior, including motility, virulence, biofilm formation, and cell cycle progression. Cyclic-di-GMP has anti-cancer cell proliferation activity and also induces elevated CD4 receptor expression and cell cycle arrest. Cyclic-di-GMP can be used in cancer research[1][2][3][4].

• Target Antigen:

  Endogenous Metabolite; STING

• Type:

  Natural Products

• Related Pathways:

  Immunology/Inflammation;Metabolic Enzyme/Protease

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/Cyclic-di-GMP.html

• Purity:

  98.18

• Solubility:

  H2O : ≥ 25 mg/mL

• Smiles:

  O[C@@H]([C@H](N1C=NC2=C1N=C(N)NC2=O)O3)[C@H](OP(O)(OC[C@@H]4[C@H]([C@H]([C@H](N5C=NC6=C5N=C(N)NC6=O)O4)O)O7)=O)[C@H]3COP7(O)=O

• Molecular Weight:

  690.41

• References & Citations:

  [1]Karaolis DK, et al. 3',5'-Cyclic diguanylic acid (c-di-GMP) inhibits basal and growth factor-stimulated human colon cancer cell proliferation. Biochem Biophys Res Commun. 2005 Apr 1;329(1):40-5. |[2]Steinberger O, et al. Elevated expression of the CD4 receptor and cell cycle arrest are induced in Jurkat cells by treatment with the novel cyclic dinucleotide 3',5'-cyclic diguanylic acid. FEBS Lett. 1999 Feb 5;444(1):125-9. |[3]Wang Z, et al. STING activator c-di-GMP enhances the anti-tumor effects of peptide vaccines in melanoma-bearing mice. Cancer Immunol Immunother. 2015 Aug;64(8):1057-66. |[4]Jenal U, et al. Cyclic di-GMP: second messenger extraordinaire. Nat Rev Microbiol. 2017 May;15(5):271-284. Gut Microbes. 2022 Jan-Dec;14(1):2119055.|Int J Biol Macromol. 2024 Sep 14:135660.|Mbio. 2021 Oct 26;12(5):e0119221.|Clin Transl Med. 2024 Aug;14(8):e1744.|NPJ Biofilms Microbiomes. 2024 Jun 20;10(1):51.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  No Development Reported

• CAS Number:

  61093-23-0